BEGIN:VCALENDAR VERSION:2.0 PRODID:-//app.ishl.eu//Schedule X-WR-CALNAME:ISHL13 CALSCALE:GREGORIAN BEGIN:VTIMEZONE TZID:Europe/Berlin TZURL:http://tzurl.org/zoneinfo-outlook/Europe/Berlin X-LIC-LOCATION:Europe/Berlin BEGIN:DAYLIGHT TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:CEST DTSTART:19700329T020000 RRULE:FREQ=YEARLY;BYMONTH=3;BYDAY=-1SU END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:CET DTSTART:19701025T030000 RRULE:FREQ=YEARLY;BYMONTH=10;BYDAY=-1SU END:STANDARD END:VTIMEZONE BEGIN:VEVENT DTSTAMP:20260818T073900 UID:session-250@app.ishl.eu/2024 DTSTART;TZID=Europe/Berlin:20241026T083000 DTEND;TZID=Europe/Berlin:20241026T110000 SUMMARY:Workshop 1 - Working towards harmonization of clinical trial reporting in Hodgkin Lymphoma LOCATION:Marsilius Saal (Gürzenich) DESCRIPTION: X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Workshop 1 - Working towards harmonization of clinical trial reporting in Hodgkin Lymphoma ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260818T073900 UID:session-251@app.ishl.eu/2024 DTSTART;TZID=Europe/Berlin:20241026T083000 DTEND;TZID=Europe/Berlin:20241026T110000 SUMMARY:Educational - EHA-LYG / GHSG Joint Educational “Emerging Therapeutic Concepts in B-Cell Lymphomas” LOCATION:Großer Saal (Gürzenich) DESCRIPTION:Talks: Introduction, Molecular and microenvironmental vulnerabilities of B-cell lymphomas, Is there a role for CAR T-cell therapy in first-line Tx of indolent lymphoma?, Who needs bispecific antibodies as first-line treatment in aggressive lymphoma?, How to implement novel ADCs in the first-line treatment of lymphoma, Perspectives of small molecule based first-line therapy of LBCL, Treatment and Trial Landscape for Malignant Lymphoma in China X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Educational - EHA-LYG / GHSG Joint Educational “Emerging Therapeutic Concepts in B-Cell Lymphomas” ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260818T073900 UID:session-252@app.ishl.eu/2024 DTSTART;TZID=Europe/Berlin:20241026T113000 DTEND;TZID=Europe/Berlin:20241026T130000 SUMMARY:Scientific Session 1 - Limited Stages LOCATION:Großer Saal (Gürzenich) DESCRIPTION:Talks: IIntro: Treatment concepts in early-stage HL, Viewpoint: Systemic Therapy only in the future?, Viewpoint: CMT (is it there to stay?), Factors driving treatment intensity in the whole cohort of patients with early-stage favorable (I-IIA), nonbulky Hodgkin Lymphoma enrolled in the RAFTING trial (NCT 04866654)., Nodular lymphocyte predominant Hodgkin lymphoma in the Nordic countries – characteristics, treatment and survival, Serum TARC Dynamics Correlate with Clinical Response and Metabolic Tumor Volume During Anti-PD1-Based First-Line HL Treatment in The GHSG Phase II NIVAHL Trial X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Scientific Session 1 - Limited Stages ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260818T073900 UID:session-253@app.ishl.eu/2024 DTSTART;TZID=Europe/Berlin:20241026T131500 DTEND;TZID=Europe/Berlin:20241026T144500 SUMMARY:Satellite Symposium - The evolving role of BTKis in the treatment of B-cell lymphomas LOCATION:Großer Saal (Gürzenich) DESCRIPTION:Talks: Welcome and Introduction, BTKis in indolent lymphomas (FL, MZL), BTKis in WM, BTKis in MCL, Future developments (CDAC, BCL2, anti PD1/PDL1), Panel discussion, audience Q&A, Closure and farewell X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Satellite Symposium - The evolving role of BTKis in the treatment of B-cell lymphomas ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260818T073900 UID:session-254@app.ishl.eu/2024 DTSTART;TZID=Europe/Berlin:20241026T151500 DTEND;TZID=Europe/Berlin:20241026T170000 SUMMARY:Main Program - Opening and Award Ceremony LOCATION:Großer Saal (Gürzenich) DESCRIPTION:Talks: Welcome Address, Award Ceremony, Keynote Lecture X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Main Program - Opening and Award Ceremony ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260818T073900 UID:session-255@app.ishl.eu/2024 DTSTART;TZID=Europe/Berlin:20241026T171500 DTEND;TZID=Europe/Berlin:20241026T200000 SUMMARY:Main Program - Poster Session & Welcome Reception LOCATION:Foyer (First Floor) (Gürzenich) DESCRIPTION:Talks: All poster presenters are required to be present at their poster boards from 17:15 to 19:00 X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Main Program - Poster Session & Welcome Reception ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260818T073900 UID:session-256@app.ishl.eu/2024 DTSTART;TZID=Europe/Berlin:20241027T080000 DTEND;TZID=Europe/Berlin:20241027T093000 SUMMARY:Scientific Session 2 - Pediatric and Adolescent Treatment Concepts LOCATION:Großer Saal (Gürzenich) DESCRIPTION:Talks: Recent achievements and future goals in Pediatric and Young Adult HL: COG Perspective, Recent achievements and future goals in Pediatric and Young Adult HL: EuroNET-PHL Perspective, Appropriate endpoints for future trials in Pediatric and Young Adult HL, and opportunities for harmonization, EFFICACY and TOLERABILITY in DECOPDAC21 versus COPDAC28 in PEDIATRIC INTERMEDIATE and ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: INTERIM RESULTS of the EURONET-PHL-C2 RANDOMIZED STUDY, Progression-Free Survival (PFS) with Nivolumab-AVD is superior to Brentuximab Vedotin-AVD with 2-year follow-up of S1826 in Adolescent Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL), Updated Results from the Phase 2 KEYNOTE-667 Study: Pembrolizumab (pembro) in Children and Young Adults With Low-Risk Classical Hodgkin Lymphoma (cHL) and Slow Early Response (SER) to Front-Line Chemotherapy (chemo) X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Scientific Session 2 - Pediatric and Adolescent Treatment Concepts ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260818T073900 UID:session-257@app.ishl.eu/2024 DTSTART;TZID=Europe/Berlin:20241027T100000 DTEND;TZID=Europe/Berlin:20241027T113000 SUMMARY:Scientific Session 3 - Biology & Microenvironment LOCATION:Großer Saal (Gürzenich) DESCRIPTION:Talks: Pathogenesis of HL, Multimodal characterization of cHL, Characterization of cancer-associated fibroblasts and their spatial architecture reveals heterogeneity and survival associations in classical Hodgkin lymphoma, Circulating tumor DNA sequencing facilitates biological classification and individualized risk stratification in patients with Hodgkin lymphoma, Distinct cell state ecosystems for nodular lymphocyte-predominant Hodgkin lymphoma, Multi-Dimensional Profiling Unveils Distinct Molecular Subtypes in Classic Hodgkin Lymphoma X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Scientific Session 3 - Biology & Microenvironment ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260818T073900 UID:session-258@app.ishl.eu/2024 DTSTART;TZID=Europe/Berlin:20241027T120000 DTEND;TZID=Europe/Berlin:20241027T133000 SUMMARY:Satellite Symposium - New concepts for the treatment of B-cell lymphomas LOCATION:Großer Saal (Gürzenich) DESCRIPTION:Talks: B-cell lymphoma pathology – illustrated for non- pathologists, Classical Hodgkin Lymphoma - Development of immune checkpoint inhibition beyond PD-1 blockade, Diffuse Large B-cell Lymphoma - The current and future role of ADC in the context of immunotherapies X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Satellite Symposium - New concepts for the treatment of B-cell lymphomas ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260818T073900 UID:session-259@app.ishl.eu/2024 DTSTART;TZID=Europe/Berlin:20241027T140000 DTEND;TZID=Europe/Berlin:20241027T153000 SUMMARY:Scientific Session 4 - Older Patients LOCATION:Großer Saal (Gürzenich) DESCRIPTION:Talks: Implementing Frailty Assessment for Treatment Guidance in HL, Optimal Use of Targeted Agents to Address Unmet Need in Older HL, A simplified frailty score predicts outcome in older patients with classical Hodgkin lymphoma treated with curative intent, Characterisation of older Hodgkin Lymphoma patients using UK registry data from 1997-2023, Feasibility and Efficacy of PET-guided BrECADD in Older Patients with Advanced-Stage classical Hodgkin Lymphoma: The Older Cohort of the International GHSG HD21 Trial, Nivolumab-AVD improves 2-year progression-free and overall survival compared to Bv-AVD in older patients aged ≥60 years with advanced stage classical Hodgkin lymphoma (cHL) enrolled on SWOG S1826 X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Scientific Session 4 - Older Patients ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260818T073900 UID:session-260@app.ishl.eu/2024 DTSTART;TZID=Europe/Berlin:20241027T160000 DTEND;TZID=Europe/Berlin:20241027T173000 SUMMARY:Satellite Symposium - Real world impact: bridging between clinical trial and real world experience in stages III & IV 1L Hodgkin Lymphoma LOCATION:Großer Saal (Gürzenich) DESCRIPTION:Talks: Welcome and introduction, Spotlight on ECHELON-1: 7-year survival data, Real-world insights: frontline treatment of stages III & IV cHL, Q&A, cHL in the real-world: a case study approach X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Satellite Symposium - Real world impact: bridging between clinical trial and real world experience in stages III & IV 1L Hodgkin Lymphoma ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260818T073900 UID:session-261@app.ishl.eu/2024 DTSTART;TZID=Europe/Berlin:20241027T180000 DTEND;TZID=Europe/Berlin:20241027T193000 SUMMARY:Scientific Session 5 - Advanced Stages LOCATION:Großer Saal (Gürzenich) DESCRIPTION:Talks: Individualized treatment de-escalation improves overall outcomes, Immune-chemotherapy overcomes the need for individualization, 2-Year Follow-up of the S1826 Study Confirms Improved Progression-Free Survival with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Advanced Stage Classic Hodgkin Lymphoma, Development and application of a validated MRD assay in Hodgkin Lymphoma, EORTC-1537-COBRA: PHASE II STUDY OF VERY EARLY FDG-PET-RESPONSE ADAPTED TARGETED THERAPY FOR ADVANCED HODGKIN LYMPHOMA. PRIMARY ANALYSIS INCLUDING VALUE OF QUANTITATIVE PET ASSESSMENT AND TARC DYNAMICS, Metabolic tumor volume after two cycles of chemotherapy in patients treated for advanced-stage Hodgkin Lymphoma: analysis of the German Hodgkin Study Group phase III HD18 and HD21 trials X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Scientific Session 5 - Advanced Stages ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260818T073900 UID:session-262@app.ishl.eu/2024 DTSTART;TZID=Europe/Berlin:20241028T080000 DTEND;TZID=Europe/Berlin:20241028T090000 SUMMARY:Scientific Session 6 - Special Situations & Cases LOCATION:Großer Saal (Gürzenich) DESCRIPTION:Talks: Treatment Approaches in Ressource Constraint Settings, HL Richter Transformation Pathologists perspective, HL Richter Transformation HL perspective, HL Richter Transformation CLL perspective X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Scientific Session 6 - Special Situations & Cases ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260818T073900 UID:session-263@app.ishl.eu/2024 DTSTART;TZID=Europe/Berlin:20241028T091500 DTEND;TZID=Europe/Berlin:20241028T101500 SUMMARY:Scientific Session 7 - NLPHL LOCATION:Großer Saal (Gürzenich) DESCRIPTION:Talks: NLPHL: HL, NHL or something else?, First-line treatment of NLPHL with HL-directed approaches, Treatment of NLPHL with NHL-directed approaches, Q&A X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Scientific Session 7 - NLPHL ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260818T073900 UID:session-264@app.ishl.eu/2024 DTSTART;TZID=Europe/Berlin:20241028T103000 DTEND;TZID=Europe/Berlin:20241028T120000 SUMMARY:Scientific Session 8 - Living Beyond Lymphoma LOCATION:Großer Saal (Gürzenich) DESCRIPTION:Talks: Late consequences of drugs used in the modern era of treatment for HL (to include anthracyclines, bleomycin, checkpoint inhibitors, ADCs), Starting Living beyond Lymphoma with HL diagnosis, Participation in and (cost-)effectiveness of the Dutch HL survivorship care program, A priori estimation of mediastinal toxicities after radiotherapy for Hodgkin Lymphoma - A secondary analysis of the HD16/17 Trial by the German Hodgkin Study Group using normal tissue complication probability calculations, Concordance between late effects reported by physicians and patients in a cohort of long-term Hodgkin lymphoma survivors: an analysis of data from nine consecutive EORTC-LYSA trials, Novel 3D speckel tracking imaging modality in detecting cardiac toxicity in asymptomatic pediatric HL survivors X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Scientific Session 8 - Living Beyond Lymphoma ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260818T073900 UID:session-265@app.ishl.eu/2024 DTSTART;TZID=Europe/Berlin:20241028T123000 DTEND;TZID=Europe/Berlin:20241028T140000 SUMMARY:Scientific Session 9 - Relapsed & Refractory HL LOCATION:Großer Saal (Gürzenich) DESCRIPTION:Talks: Updated approach to second-line treatment, Emerging strategies to overcome anti-PD1 resistance, Implementing raditoherapeutic concepts in rrHL care, Brentuximab Vedotin - ESHAP Significantly Increases the Metabolic Complete Remission Rate versus ESHAP in Relapsed Classical Hodgkin’s Lymphoma. Final Results of the BRESELIBET Prospective Trial., Longitudinal circulating tumor DNA sequencing may predict the response to PD1 blockade therapy in relapsed/refractory classical Hodgkin Lymphoma patients, Pembrolizumab maintenance instead of autologous hematopoietic cell transplantation for patients with relapsed or refractory Hodgkin lymphoma in complete response after pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Scientific Session 9 - Relapsed & Refractory HL ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260818T073900 UID:session-266@app.ishl.eu/2024 DTSTART;TZID=Europe/Berlin:20241028T140000 SUMMARY:Main Program - Closing remarks LOCATION:Großer Saal (Gürzenich) DESCRIPTION:Talks: Workshop Report, Best of ISHL13, Farewell X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Main Program - Closing remarks ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT END:VCALENDAR